Suppr超能文献

构建和验证免疫浸润相关风险模型预测低级别胶质瘤的预后和免疫治疗反应。

Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.

机构信息

Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110000, China.

Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, 110000, China.

出版信息

BMC Cancer. 2023 Aug 5;23(1):727. doi: 10.1186/s12885-023-11222-5.

Abstract

BACKGROUND

Low grade glioma (LGG) is considered a heterogeneous tumor with highly variable survival and limited efficacy of immunotherapy. To identify high-risk subsets and apply immunotherapy effectively in LGG, the status and function of immune infiltration in the glioma microenvironment must be explored.

METHODS

Four independent glioma cohorts comprising 1,853 patients were enrolled for bioinformatics analysis. We used ConsensusClusterPlus to cluster patients into four different immune subtypes based on immune infiltration. The immune-infiltration signature (IIS) was constructed by LASSO regression analysis. Somatic mutation and copy number variation (CNV) analyses were performed to explore genomic and transcriptomic traits in the high- and low- risk groups. The correlation between response to programmed cell death 1 (PD-1) blockade and the IIS risk score was confirmed in an in vivo glioma model.

RESULTS

Patients were clustered into four different immune subtypes based on immune infiltration, and the high immune infiltration subtype was associated with worse survival in LGG. The high immune infiltration subtype had stronger inflammatory response, immune response and immune cell chemotaxis. The IIS, consisting of EMP3, IQGAP2, METTL7B, SLC1A6 and TNFRSF11B, could predict LGG malignant progression, which was validated with internal clinical samples. M2 macrophage infiltration positively correlated with the IIS risk score. The high-risk group had significantly more somatic mutations and CNVs. The IIS risk score was related to immunomodulatory molecules and could predict immunotherapy clinical benefit. In vivo, immunotherapy-sensitive glioma model exhibited higher IIS risk score and more infiltration of immune cells, especially M2 macrophages. The IIS risk score was decreased in an immunotherapy-sensitive glioma model after anti-PD1 immunotherapy.

CONCLUSION

Different immune subtypes of LGG had unique immune cell infiltration characteristics, and the high immune infiltration subtype was associated with immunosuppressive signaling pathways. A novel IIS prognostic model based on immune infiltration status was constructed for immunophenotypic classification, risk stratification, prognostication and immunotherapy response prediction in LGG.

摘要

背景

低级别胶质瘤(LGG)被认为是一种具有高度异质性的肿瘤,其生存时间差异很大,免疫疗法的疗效有限。为了确定高危亚群并有效地在 LGG 中应用免疫疗法,必须探索胶质瘤微环境中免疫浸润的状态和功能。

方法

纳入了包含 1853 名患者的四个独立的胶质瘤队列进行生物信息学分析。我们使用 ConsensusClusterPlus 根据免疫浸润将患者分为四个不同的免疫亚型。通过 LASSO 回归分析构建免疫浸润特征(IIS)。进行体细胞突变和拷贝数变异(CNV)分析,以探索高、低风险组的基因组和转录组特征。在体内胶质瘤模型中证实了对程序性细胞死亡 1(PD-1)阻断的反应与 IIS 风险评分之间的相关性。

结果

根据免疫浸润将患者分为四个不同的免疫亚型,高免疫浸润亚型与 LGG 的生存预后较差相关。高免疫浸润亚型具有更强的炎症反应、免疫反应和免疫细胞趋化性。由 EMP3、IQGAP2、METTL7B、SLC1A6 和 TNFRSF11B 组成的 IIS 可以预测 LGG 的恶性进展,这在内部临床样本中得到了验证。M2 巨噬细胞浸润与 IIS 风险评分呈正相关。高危组有更多的体细胞突变和 CNV。IIS 风险评分与免疫调节分子相关,可以预测免疫治疗的临床获益。在体内,免疫治疗敏感的胶质瘤模型表现出更高的 IIS 风险评分和更多的免疫细胞浸润,特别是 M2 巨噬细胞。在抗 PD-1 免疫治疗后,免疫治疗敏感的胶质瘤模型中的 IIS 风险评分降低。

结论

不同免疫亚型的 LGG 具有独特的免疫细胞浸润特征,高免疫浸润亚型与免疫抑制信号通路相关。构建了一种基于免疫浸润状态的新的 IIS 预后模型,用于 LGG 的免疫表型分类、风险分层、预后预测和免疫治疗反应预测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e755/10403952/275e564973eb/12885_2023_11222_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验